Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company focused on medicines for genetically defined conditions. This news page aggregates company announcements, press releases and event updates so readers can follow how BioMarin’s strategy, pipeline and commercial portfolio evolve over time.
Recent communications from BioMarin highlight its emphasis on Enzyme Therapies and Skeletal Conditions business units, as well as its work with ROCTAVIAN, a gene therapy for hemophilia A. The company issues news on topics such as financial results, long-term guidance, corporate strategy, business development transactions, clinical data presentations and regulatory milestones for its therapies.
Examples of news themes include updates on VOXZOGO in achondroplasia and other skeletal conditions, progress with PALYNZIQ in phenylketonuria, development of BMN 401 for ENPP1 deficiency and other pipeline programs in rare genetic diseases. BioMarin also reports on strategic partnerships, such as digital and data collaborations, and on planned acquisitions intended to expand and diversify its rare disease portfolio.
Investors and followers of BMRN can use this page to review earnings announcements, conference presentations, investor day materials and product-specific updates released through newswires. By checking this feed regularly, readers can see how BioMarin describes its growth priorities, clinical milestones and capital allocation decisions across its rare disease franchises.
BioMarin Pharmaceutical announced participation in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020, at 11:30 AM ET. Key representatives, Henry Fuchs, M.D., President of Worldwide Research & Development, and Brian Mueller, Acting CFO, will present. The event will feature a live audio webcast accessible via the company's investor site. BioMarin focuses on innovative therapies for serious rare disorders, with six commercialized products and numerous candidates in development.
BioMarin Pharmaceutical has released new data from a four-year update of its Phase 1/2 trial for valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, presented by Professor John Pasi. Results indicate a 95% reduction in Annualized Bleed Rate (ABR) to 0.8 from a baseline of 16.3 after four years. Notably, 86% of participants were bleed-free in the fourth year, and there was a 96% reduction in Factor VIII usage. The FDA is reviewing the therapy for approval, with a PDUFA date set for August 21, 2020. The safety profile remains consistent, with no severe adverse events reported.